NewAmsterdam Pharma Co N.V.NAMSEarnings & Financial Report
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
Revenue
$12.8M
Gross Profit
N/A
Operating Profit
$-43.2M
Net Profit
$-92.2M
Gross Margin
N/A
Operating Margin
-338.5%
Net Margin
-721.7%
YoY Growth
N/A
EPS
$-0.91
NewAmsterdam Pharma Co N.V. Q4 FY2024 Financial Summary
NewAmsterdam Pharma Co N.V. reported revenue of $12.8M for Q4 FY2024, with a net profit of $-92.2M (-721.7% margin).
Key Financial Metrics
| Total Revenue | $12.8M |
|---|---|
| Net Profit | $-92.2M |
| Gross Margin | N/A |
| Operating Margin | -338.5% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
NewAmsterdam Pharma Co N.V. Q4 FY2024 revenue of $12.8M breaks down across 2 segments, led by Menarini International Licensing Agreement at $11.9M (93.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Menarini International Licensing Agreement | $11.9M | 93.2% |
| Other | $872.0K | 6.8% |
NewAmsterdam Pharma Co N.V. Quarterly Revenue & Net Profit History
NewAmsterdam Pharma Co N.V. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $19.1M | +740.1% | $-17.4M | -90.7% |
| Q4 FY2024 | $12.8M | — | $-92.2M | -721.7% |
| Q3 FY2024 | $29.1M | — | $-16.6M | -57.2% |
| Q1 FY2023 | $8.6M | — | $-42.0M | -486.9% |
Income Statement
| Q1 2023 | Q3 2024 | Q4 2024 | Q2 2025 | |
|---|---|---|---|---|
| Revenue | $8.6M | $29.1M | $12.8M | $19.1M |
| YoY Growth | N/A | N/A | N/A | 740.1% |
Balance Sheet
| Q1 2023 | Q3 2024 | Q4 2024 | Q2 2025 | |
|---|---|---|---|---|
| Assets | N/A | $439.2M | $864.6M | $815.1M |
| Liabilities | N/A | $60.3M | $107.1M | $36.6M |
| Equity | $398.4M | $378.9M | $757.5M | $778.5M |
Cash Flow
| Q1 2023 | Q3 2024 | Q4 2024 | Q2 2025 | |
|---|---|---|---|---|
| Operating CF | $-31.9M | $-12.5M | $-37.5M | $-37.7M |